A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

BACKGROUND: Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseli...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Heart Fail
Auteurs principaux: McMurray, John J.V., DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna M., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D.
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Ltd 2019
Sujets:
Trial Designs
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6607736/
https://ncbi.nlm.nih.gov/pubmed/30895697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1432
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires